All In Biotech

Drug Trial Radar · NCT07373535

Understanding Music and Mindfulness Preferences in Psilocybin-Assisted Psychotherapy

Toward Patient-Tailored Care for Treatment-Resistant Depression: A Pilot Patient-Preference Clinical Trial of Music and Mindfulness in Psilocybin-Assisted Psychotherapy

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

16

Planned (sponsor's estimate)

Start

Dec 2026

Primary completion

Dec 2028

Study completion Dec 2028

Sponsor

Lead sponsor
Kyle GreenwayAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this pilot clinical trial is to learn whether it is feasible to individually tailor psilocybin-assisted psychotherapy (PAP) for people with treatment-resistant depression (TRD) based on their personal preferences. The study also aims to explore whether two different psychotherapy styles, music-centered and mindfulness-centered, influence how people respond to psilocybin treatment. The main questions it aims to answer are: * Is it feasible to conduct a patient-preference randomized trial of psilocybin-assisted psychotherapy? * Does receiving a preferred psychotherapy style improve treatment experiences or outcomes? * How do music-centered and mindfulness-centered PAP approaches compare in their effects on improving mood and well-being? Researchers will compare music-centered PAP to mindfulness-centered PAP to see if aligning psychotherapy with individual preferences is a practical and potentially beneficial approach for improving treatment efficacy and tolerability. Participants will: * Be adults with treatment-resistant depression * Receive two 25 mg psilocybin (PEX010, Filament Health) sessions, spaced four weeks apart * Experience one session with music-centered psychotherapy and one with mindfulness-centered psychotherapy * Before treatment, rate their preference for the two psychotherapy approaches * Be randomly assigned to receive their preferred or non-preferred approach first, followed by the other * Complete preparation and integration sessions before and after each psilocybin session This feasibility trial will also collect information on participants' cultural and personal factors influencing psychotherapy preferences using a modified Cultural Formulation Interview, and explore physiological measures of therapeutic alliance, an important factor in psychotherapy outcomes.

Conditions

  • Treatment-Resistant Major Depressive Disorder

Interventions

  • Psilocybin 25mgDrug

    Psilocybin 25mg

  • Music-centered psilocybin-assisted therapyOther

    Psilocybin therapy emphasizing the use of music.

  • Mindfulness-centered psilocybin-assisted therapyOther

    Psilocybin therapy emphasizing the use of guided mindfulness.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Enrollment FeasibilityTime frame: From screening through enrollment
  2. Overall Trial Completion FeasibilityTime frame: From enrollment through the end of active treatment (Week 10)
  3. Trial Completion by Preference AssignmentTime frame: From enrollment through the end of active treatment (Week 10)
  4. Distribution of Treatment PreferencesTime frame: Baseline
  5. Ease of Delivering Treatment Approaches as Assessed by the NASA-TLXTime frame: End of each psilocybin treatment session (Week 3, Week 9)
  6. Theoretical Framework of Acceptability (TFA)Time frame: Baseline, Weeks 3 and 9 (treatment sessions), Week 11 (follow-up)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Jewish General Hospital

    Montreal, Quebec, Canada

  • Jewish General Hospital

    Montreal, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.